Taken together, these findings establish FZD7 as a marker of tumor-initiating basal cells in TNBC, demonstrate the efficacy of a highly selective FZD7-ADC, and highlight the translational utility of organoid models in preclinical cancer research. Here, FZD7 is linked to neoplasm.